Skip to main content

3 Result(s)

within Michael Burgess Remove this filter Cancer Research Remove this filter

and

  1. No Access

    Article

    Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979)

    The impact of zosuquidar.3HCl, an inhibitor of P-glycoprotein, on the pharmacokinetics of daunorubicin and daunorubicinol was examined in a phase I trial using a population approach. Pharmacokinetic and pharma...

    Sophie Callies, Dinesh P. de Alwis, Atul Mehta… in Cancer Chemotherapy and Pharmacology (2004)

  2. No Access

    Article

    A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)

    Abstract

    Sophie Callies, Dinesh P. de Alwis, James G. Wright… in Cancer Chemotherapy and Pharmacology (2003)

  3. No Access

    Article

    Clinical pharmacology of 4-demethoxydaunorubicin (DMDR)

    DMDR, a daunorubicin derivative with a higher therapeutic index and lower cardiotoxicity than either the parent drug or doxorubicin, is active when given PO in experimental animals. We studied its pharmacokine...

    Katherine Lu, Niramol Savaraj, John Kavanagh… in Cancer Chemotherapy and Pharmacology (1986)